MedTrace Logo

Albuterol and Immune Cell Composition

NCT03889379 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2021-08-13

No results posted yet for this study

Summary

The aim of this pilot study is to determine the effects of albuterol on the composition of immune cells in the bloodstream for possible future use in patients with neuroblastoma.

Conditions

  • Immune Cell Composition

Interventions

DRUG

Administration of albuterol

Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.

Sponsors & Collaborators

  • University of Arizona

    lead OTHER

Principal Investigators

  • Grace M Niemiro, PhD · University of Arizona

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
44 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-20
Primary Completion
2021-06-20
Completion
2021-06-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03889379 on ClinicalTrials.gov